lurbinectedin

June 23, 2017June 23, 2017

PharmaMar’s Lurbinectedin to Be Marketed as Zepsyre After Approval as Ovarian Cancer Therapy

News

Once approved, PharmaMar’s lurbinectedin (PM1183) will be marketed under the brand name Zepsyre as a treatment for solid tumors in ovarian, lung, and breast cancers. Zepsyre is in its final stage of development as ... Read more

April 12, 2017April 12, 2017

PharmaMar Presents New Data on Plitidepsin, Lurbinectedin Therapies to Treat Ovarian Cancer, Multiple Myeloma

News

Plitidepsin and lurbinectedin, two drugs advancing in clinical studies for the treatment of ovarian cancer and other malignancies, were the focus of two PharmaMar presentations at the April 1-5 American Association of Cancer Research (AACR) ... Read more